Nuvation Bio Q3 EPS Forecast Decreased by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB) – Equities researchers at HC Wainwright reduced their Q3 2025 earnings per share (EPS) estimates for Nuvation Bio in a research note issued on Thursday, January 23rd. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.16) per share for the quarter, down from their prior estimate of ($0.14). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.62) EPS.

Nuvation Bio (NYSE:NUVB) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The company had revenue of $0.73 million during the quarter.

Several other brokerages have also issued reports on NUVB. Wedbush reiterated an “outperform” rating and issued a $5.00 price target on shares of Nuvation Bio in a research note on Monday, January 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 target price (up from $6.00) on shares of Nuvation Bio in a report on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Nuvation Bio presently has a consensus rating of “Buy” and an average price target of $8.20.

Nuvation Bio Stock Down 1.2 %

NUVB opened at $2.49 on Monday. Nuvation Bio has a 12-month low of $1.52 and a 12-month high of $4.16. The stock has a market cap of $838.40 million, a price-to-earnings ratio of -1.15 and a beta of 1.47. The business has a 50 day moving average of $2.74 and a 200-day moving average of $2.78.

Hedge Funds Weigh In On Nuvation Bio

A number of hedge funds have recently added to or reduced their stakes in the company. B. Riley Wealth Advisors Inc. bought a new position in Nuvation Bio in the 2nd quarter worth $29,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Nuvation Bio by 913.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 11,095 shares of the company’s stock valued at $32,000 after acquiring an additional 10,000 shares during the last quarter. Xponance Inc. purchased a new stake in Nuvation Bio in the 2nd quarter worth about $33,000. Caxton Associates LP purchased a new stake in Nuvation Bio in the 2nd quarter worth about $43,000. Finally, Profund Advisors LLC purchased a new stake in Nuvation Bio in the 2nd quarter worth about $63,000. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.